• Single-cell sequencing reveals the heterogeneity and intratumoral crosstalk in human endometrial cancer 

  Yu, Z; Zhang, J; Zhang, Q; Wei, S; Shi, R; Zhao, R; An, L; Grose, R; Feng, D; Wang, H (2022-05-13)

  Background: Endometrial cancer (EC) is one of the most common gynecologic malignancies with increasing morbidity. Cell–cell and cell-matrix interactions within the tumour microenvironment (TME) exert a powerful influence ...

• Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion 

  Murray, ER; Menezes, S; Henry, JC; Williams, JL; Alba-Castellon, L; Baskaran, P; Quetier, I; Desai, A; Marshall, JJT; Rosewell, I (2022-01-25)

• Shining light on dark selection in healthy human tissues 

  Werner, B (2021-11)

• Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. 

  Lote, H; Spiteri, I; Ermini, L; Vatsiou, A; Roy, A; McDonald, A; Maka, N; Balsitis, M; Bose, N; Simbolo, M (2017-06-01)

  Background: Patients often ask oncologists how long a cancer has been present before causing symptoms or spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic approaches but ...

• Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer 

  Sivapalan, L; Thorn, GJ; Gadaleta, E; Kocher, HM; Ross-Adams, H; Chelala, C (2022-04-07)

• Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. 

  Therizols, G; Bash-Imam, Z; Panthu, B; Machon, C; Vincent, A; Ripoll, J; Nait-Slimane, S; Chalabi-Dchar, M; Gaucherot, A; Garcia, M (2022-01-10)

  Mechanisms of drug-tolerance remain poorly understood and have been linked to genomic but also to non-genomic processes. 5-fluorouracil (5-FU), the most widely used chemotherapy in oncology is associated with resistance. ...

• P032. The role of P-cadherin in early breast cancer risk stratification 

  Allen, N; Allen, M; Gomm, J; Jones, L; Don't know (2021-05-01)

• P020. Defining molecular signatures to personalise management of patients with early breast cancer 

  Allen, N; Allen, M; Gomm, J; Nelan, R; Nagano, A; Chelala, C; Jones, L (2021-05-01)

• Improved Immunotherapy Efficacy by Vascular Modulation 

  Newport, EL; Rita Pedrosa, A; Njegic, A; Hodivala-Dilke, KM; Munoz-Felix, JM (2021-10)

• COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London 

  Ullah, AZMD; Sivapalan, L; Kocher, HM; Chelala, C (2021)

• Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience 

  McKay, SC; Pathak, S; Wilkin, RJW; Kamarajah, SK; Wigmore, SJ; Rees, J; Dunne, DFJ; Garcea, G; Ahmad, J; Carino, NDL (2021-11)

• Temporality of clinical factors associated with pancreatic cancer: a case-control study using linked electronic health records 

  Ullah, AZMD; Stasinos, K; Chelala, C; Kocher, HM (2021-11-27)

• Natural killer cells in pancreatic cancer stroma 

  Fincham, REA; Delvecchio, FR; Goulart, MR; Yeong, JPS; Kocher, HM (2021-06-28)

• FGF signalling facilitates cervical cancer progression 

  Mahmood, H-T-NA; Bort, ET; Walker, AJ; Grose, RP; Chioni, A-M (2022-01-03)

• Centrosome amplification mediates small extracellular vesicle secretion via lysosome disruption 

  Adams, SD; Csere, J; D'angelo, G; Carter, EP; Romao, M; Arnandis, T; Dodel, M; Kocher, HM; Grose, R; Raposo, G (2021-04-12)

• Biological Significance and Targeting of the FGFR Axis in Cancer 

  Chioni, A-M; Grose, RP (2021-11)

• Tumour microenvironment 3D-modelling: simplicity to complexity and back again 

  Carter, EP; Roozitalab, R; Gibson, SV; Grose, RP (2021-11)

• Quantitative Super-Resolution Imaging for the Analysis of GPCR Oligomerization 

  Joseph, MD; Bort, ET; Grose, RP; McCormick, PJ; Simoncelli, S (2021-10)

• Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy 

  Jomrich, G; Kollmann, D; Wilfing, L; Radosavljevic, S; Ramazanova, D; Ristl, R; Grose, RP; Ilhan-Mutlu, A; Preusser, M; Fassnacht, C (2021-12)

• Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. 

  Harrod, A; Fulton, J; Nguyen, VTM; Periyasamy, M; Ramos-Garcia, L; Lai, C-F; Metodieva, G; de Giorgio, A; Williams, RL; Santos, DB (Springer Nature, 2017-04-20)

  Drugs that inhibit estrogen receptor-α (ER) activity have been highly successful in treating and reducing breast cancer progression in ER-positive disease. However, resistance to these therapies presents a major clinical ...

View more